Captor Therapeutics ®
News
August 10, 2022
Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
July 21, 2022
Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
June 30, 2022
Zaproszenie na Walne Zgromadzenie
May 31, 2022
Captor Therapeutics Q1 2022 report: company continues to generate exciting data on lead projects (CT-01, CT-02, CT-03), maintains strong financial position
May 05, 2022
Captor Therapeutics to host R&D Day on May 18, 2022
May 02, 2022
Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule
April 20, 2022
Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinoma
April 11, 2022
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma